Amgen hangs on to Kite in CAR-T race

Amgen is jumping into the CAR-T fray by signing a significant deal with Kite Pharma. The companies are partnering to develop novel chimeric antigen receptor T cell (CAR-T) immunotherapies based on Kite's engineered autologous cell therapy (eACT) platform and cancer targets from Amgen.